BACKGROUND AND OBJECTIVES: Sentinel node (SN) biopsy is a minimally invasive surgical method for axillary staging in patients with breast cancer. The aim of this study was to evaluate mid-term morbidity after SN biopsy and axillary lymph node (ALN) dissection in patients with breast cancer receiving breast-sparing treatment, and to determine its impact on quality of life (QOL). METHODS: One hundred fifteen patients with breast cancer underwent breast-conserving treatment with SN biopsy alone (Group 1: n = 54), ALN dissection with or without SN biopsy (Group 2: n = 51), or SN biopsy followed by later ALN dissection (Group 3: n = 10). RESULTS: The mean post-operative follow-up was 20.3 months (range: 10-31 months) in Group 1, 24.3 months (range: 10-33 months) in Group 2, and 19.1 months (range: 12-28 months) in Group 3. Arm-shoulder pain was reported by 21.2% of patients in Group 1, 52.9% in Group 2, and 60% in Group 3 (P = 0.002). An arm swelling sensation was reported by 0% of patients in Group 1, 21.6% in Group 2, and 10% in Group 3. Dysesthesias were reported by 5.7% of patients in Group 1, 51% in Group 2, and 50% in Group 3 (P < 0.001). The mean global QOL self-rating score was 7.6 in Group 1, 7.6 in Group 2, and 7.7 in Group 3 (no significant difference). CONCLUSIONS: SN biopsy is associated with significantly lower mid-term morbidity than ALN dissection.
BACKGROUND AND OBJECTIVES: Sentinel node (SN) biopsy is a minimally invasive surgical method for axillary staging in patients with breast cancer. The aim of this study was to evaluate mid-term morbidity after SN biopsy and axillary lymph node (ALN) dissection in patients with breast cancer receiving breast-sparing treatment, and to determine its impact on quality of life (QOL). METHODS: One hundred fifteen patients with breast cancer underwent breast-conserving treatment with SN biopsy alone (Group 1: n = 54), ALN dissection with or without SN biopsy (Group 2: n = 51), or SN biopsy followed by later ALN dissection (Group 3: n = 10). RESULTS: The mean post-operative follow-up was 20.3 months (range: 10-31 months) in Group 1, 24.3 months (range: 10-33 months) in Group 2, and 19.1 months (range: 12-28 months) in Group 3. Arm-shoulder pain was reported by 21.2% of patients in Group 1, 52.9% in Group 2, and 60% in Group 3 (P = 0.002). An arm swelling sensation was reported by 0% of patients in Group 1, 21.6% in Group 2, and 10% in Group 3. Dysesthesias were reported by 5.7% of patients in Group 1, 51% in Group 2, and 50% in Group 3 (P < 0.001). The mean global QOL self-rating score was 7.6 in Group 1, 7.6 in Group 2, and 7.7 in Group 3 (no significant difference). CONCLUSIONS: SN biopsy is associated with significantly lower mid-term morbidity than ALN dissection.
Authors: Dionysios Dellaportas; Andreas Koureas; John Contis; Panagis M Lykoudis; Irene Vraka; Dimitrios Psychogios; Agatha Kondi-Pafiti; Dionysios K Voros Journal: Breast Care (Basel) Date: 2015-07-10 Impact factor: 2.860
Authors: Igor Langer; Ulrich Guller; Gilles Berclaz; Ossi R Koechli; Gabriel Schaer; Mathias K Fehr; Thomas Hess; Daniel Oertli; Lucio Bronz; Beate Schnarwyler; Edward Wight; Urs Uehlinger; Eduard Infanger; Daniel Burger; Markus Zuber Journal: Ann Surg Date: 2007-03 Impact factor: 12.969
Authors: Juan Ignacio Arraras; Ana Manterola; Miguel Angel Domínguez; Fernando Arias; Elena Villafranca; Pilar Romero; Enrique Martínez; José Juan Illarramendi; Esteban Salgado Journal: Clin Transl Oncol Date: 2008-08 Impact factor: 3.405
Authors: Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee Journal: J Clin Oncol Date: 2008-10-06 Impact factor: 44.544
Authors: Jan Kootstra; Josette E H M Hoekstra-Weebers; Hans Rietman; Jaap de Vries; Peter Baas; Jan H B Geertzen; Harald J Hoekstra Journal: Ann Surg Oncol Date: 2008-07-03 Impact factor: 5.344